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Abstract
Background: The importance of bacterial infections following respiratory syncytial virus (RSV) remains unclear. We
evaluated whether variations in RSV epidemic timing and magnitude are associated with variations in pneumococcal
disease epidemics and whether changes in pneumococcal disease following the introduction of seven-valent pneumococcal
conjugate vaccine (PCV7) were associated with changes in the rate of hospitalizations coded as RSV.
Methods and Findings: We used data from the State Inpatient Databases (Agency for Healthcare Research and Quality),
including .700,000 RSV hospitalizations and .16,000 pneumococcal pneumonia hospitalizations in 36 states (1992/1993–
2008/2009). Harmonic regression was used to estimate the timing of the average seasonal peak of RSV, pneumococcal
pneumonia, and pneumococcal septicemia. We then estimated the association between the incidence of pneumococcal
disease in children and the activity of RSV and influenza (where there is a well-established association) using Poisson
regression models that controlled for shared seasonal variations. Finally, we estimated changes in the rate of
hospitalizations coded as RSV following the introduction of PCV7. RSV and pneumococcal pneumonia shared a distinctive
spatiotemporal pattern (correlation of peak timing: r = 0.70, 95% CI: 0.45, 0.84). RSV was associated with a significant
increase in the incidence of pneumococcal pneumonia in children aged ,1 y (attributable percent [AP]: 20.3%, 95% CI:
17.4%, 25.1%) and among children aged 1–2 y (AP: 10.1%, 95% CI: 7.6%, 13.9%). Influenza was also associated with an
increase in pneumococcal pneumonia among children aged 1–2 y (AP: 3.2%, 95% CI: 1.7%, 4.7%). Finally, we observed a
significant decline in RSV-coded hospitalizations in children aged ,1 y following PCV7 introduction (218.0%, 95% CI:
222.6%, 213.1%, for 2004/2005–2008/2009 versus 1997/1998–1999/2000). This study used aggregated hospitalization data,
and studies with individual-level, laboratory-confirmed data could help to confirm these findings.
Conclusions: These analyses provide evidence for an interaction between RSV and pneumococcal pneumonia. Future work
should evaluate whether treatment for secondary bacterial infections could be considered for pneumonia cases even if a
child tests positive for RSV.
Please see later in the article for the Editors’ Summary.
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contradictions among previous studies of pneumococcus–RSV coinfection.

Introduction
Respiratory infections caused by viruses and bacteria account
for a substantial burden of disease in children throughout the
world. Co-infections of bacteria and viruses can have a synergistic
effect and lead to more severe disease and hospitalization. In order
to design and implement more effective interventions against
respiratory infections, it is critical to better understand these
interactions. The classic example of this type of interaction is
between pneumococcus and influenza. Influenza infections
increase the risk for pneumococcal disease during both pandemic
and inter-pandemic periods [1–8]. However, there is some
evidence that pneumococcus also interacts with respiratory
syncytial virus (RSV), which causes a large proportion of
respiratory infections in young children [9]. Children hospitalized
with RSV in Denmark had an elevated risk for developing invasive
pneumococcal disease during the following month [10], and time
series analyses that controlled for seasonality found an association
between RSV activity and invasive pneumococcal disease [11,12].
Additionally, a randomized controlled trial of the pneumococcal
vaccine in South Africa found that HIV-negative vaccine
recipients had a 32% lower risk for hospitalization with proven
RSV-associated pneumonia than unvaccinated children [13].
Finally, sequential infections of mice with RSV and pneumococcus
demonstrate that the primary viral infection decreases bacterial
clearance from the lung [14] and increases bacterial virulence
[15]. These observations of an association between pneumococcus
and RSV seemingly contradict clinical findings that bacteremia
rarely occurs in children hospitalized with RSV [16], as well as a
recent study from England and Wales that found no association
between RSV and invasive pneumococcal disease in children aged
,5 y [17].
Quantifying the relationship between RSV and pneumococcal
infections can be difficult because of the fact that rates of disease
caused by both pathogens increase during winter months. The
interaction could be evaluated in the context of a randomized
controlled vaccine trial (as was done in South Africa [13]), in
studies that evaluate the prevalence of the virus and bacteria
among cases and controls, and in analyses of seasonal [4] and
long-term trends at the population level. Numerous studies have
identified a correlation between pneumococcal incidence and
RSV activity, but these studies can be difficult to interpret because
both pathogens have seasonal patterns and likely share other
unexplained risk factors [4,18–21]. However, such ecological
studies can be informative if the analyses control for seasonality
using either weather variables [12,17] or other variables that
change seasonally [11,22]. To convincingly establish a relationship
between these two pathogens, one must demonstrate that they
share similar spatiotemporal epidemic patterns across diverse
geographical locations and that interventions that target one of the
pathogens influence the incidence of the other.
In this study, we explored the relationship between RSV and
pneumococcal disease using data from a large multi-state
hospitalization database from the United States. We considered
whether RSV and pneumococcal pneumonia share a similar
spatiotemporal pattern across the US. We then quantified the
association between RSV and pneumococcal pneumonia and
pneumococcal septicemia while controlling for shared seasonal
variations and influenza activity using harmonic regression.
Finally, we evaluated whether pediatric vaccination with sevenvalent pneumococcal conjugate vaccine (PCV7) was associated
with a decline in the incidence of hospitalizations coded as RSV.
We discuss how these findings could help to resolve the apparent
PLOS Medicine | www.plosmedicine.org

Methods
Data Sources and Extraction
Weekly hospitalization data were obtained from the State
Inpatient Databases of the Healthcare Cost and Utilization
Project, maintained by the Agency for Healthcare Research and
Quality, through an active collaboration. These database contains
all hospital discharge records from community hospitals in
participating states [23]. For these analyses, data were available
from 1992/1993 to 2008/2009. Data were not available for all
states for all years (Figure S1). The pneumococcal vaccine was
introduced in the United States in 2000. For analyses of postPCV7 changes in incidence, we used data from the 18 states that
had at least two seasons of pre-PCV7 data and three seasons of
post-PCV7 data. For the analyses of epidemic timing, we
estimated timing using data only from states that had an average
of at least ten hospitalizations per year for the outcome being
evaluated. Data about population sizes for each state were
obtained from Census Bureau statistics compiled by the Surveillance, Epidemiology, and End Results Program [24]. All analyses
were performed in SAS version 9.2 (SAS Institute, Cary, North
Carolina).
Cases were identified by the presence of the relevant diagnostic
discharge codes listed anywhere in the patient’s discharge record,
including pneumococcal pneumonia/lobar pneumonia (International Classification of Diseases, Ninth Revision [ICD-9], code
481), pneumococcal septicemia (038.2), respiratory syncytial virus
(079.6, 466.11, 480.1), influenza (487.0–487.9), and bronchiolitis
(466). Cases were aggregated by week, disease outcome, state, and
age stratum (0–11 mo, 12–23 mo). We further subdivided the ,
1-y-old age group into the groups 0–2 mo and 3–11 mo because
serotype replacement following pneumococcal vaccination has
been more severe among neonates than among older children
[25]. The variable used to create the age strata 0–2 mo and 3–
11 mo was available for fewer states (Arizona, California,
Colorado, Georgia, Iowa, Kansas, Massachusetts, New York,
South Carolina) than the variable used to create the age strata 0–
11 mo and 12–23 mo (Figure S1). When fitting the regression
models containing influenza and RSV as covariates, we used the
total viral incidence across all age categories to minimize potential
biases related to testing in specific age strata. As a sensitivity
analysis for the RSV coding, we repeated the regression but
substituted weekly bronchiolitis among , 1-y-old children for the
RSV variable.

Harmonic Regression to Estimate Epidemic Timing
We used regression models to estimate the average peak timing
of RSV, pneumococcal pneumonia, and pneumococcal septicemia
among , 2-y-old children by state. The outcome variable was
disease incidence in each state, as measured by hospitalizations,
and the predictors were sine and cosine terms with periods of
52.25 and 104.5 wk. These harmonic terms capture both annual
and biennial epidemic patterns [26]. Data were included from
1992/1993 to 2008/2009, as available (Figure S1). In order to
adjust for changes in overall incidence caused by vaccination or
coding changes, an offset term was included that was equal to the
average incidence for the corresponding 12-mo July–June period.
The model was
2
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lnðcases=yearly averageÞ~b0 zb1  sinðhÞzb2  cosðhÞ
zb3  sinðWÞzb4  cosðWÞ

The percent of pneumococcal disease hospitalizations attributable to influenza or to RSV were calculated based on the model
estimates [8,22]: we obtained an estimate of the predicted
incidence of pneumococcal disease hospitalizations in each week
using the equation above, inserting estimates for each of the
parameters along with the observed weekly values of influenza and
RSV hospitalization rates. To obtain an estimate of the expected
incidence of pneumococcal disease if influenza or RSV was not
present, we used this same equation (without refitting the model)
and set the influenza or RSV term equal to zero. The overall
predicted incidence and the predicted incidence with the incidence
of influenza or RSV set to zero were then summed across all
weeks. The incidence of pneumococcal disease attributable to
RSV or attributable to influenza was estimated by subtracting the
prediction where viral activity was set to zero from the overall
prediction. The attributable percent (AP) is defined as the viralattributable incidence divided by the total predicted incidence.
95% confidence intervals were estimated using a seasonal block
bootstrap with 1,000 replicates [28].

ð1Þ

where h = 2*p*week/52.25 and F = 2*p*week/104.5, representing
1-y and 2-y epidemic cycles, respectively. The timing of the
epidemic peak (phase angle) and the confidence intervals were
calculated from the regression coefficients of the 1-y sine and
cosine terms (b1 and b2), as described in [26], and then converted
from radians to weeks [26]. The scale was shifted so that the
minimum value (RSV in Florida) was week 1. The timing of RSV
epidemics was compared with the timing of pneumococcal
pneumonia or septicemia epidemics using Pearson’s correlations.
Poisson regression was used to fit the model to the pneumococcal
pneumonia and pneumococcal septicemia time series. Because the
RSV data exhibited evidence of overdispersion, we used negative
binomial regression, rather than Poisson regression, to fit the
model to the RSV time series. The choice of using Poisson or
negative binomial regression influences the standard errors of the
estimates but would not be expected to influence the point
estimates. The regressions were fit separately for each state and
outcome.

Post-PCV7 Changes in RSV Incidence
We quantified changes in the incidence of RSV, pneumococcal
pneumonia, and pneumococcal septicemia hospitalizations following PCV7 introduction in 2000. The change in incidence in each
post-vaccine year (2000/2001–2008/2009) in each state was
estimated by dividing the yearly incidence by the average prevaccine incidence (1997/1998–1999/2000). To obtain an overall
estimate for vaccine-associated changes across all states, we fit a
negative binomial regression model where the outcome variable
was the yearly incidence of RSV, pneumococcal pneumonia, or
pneumococcal septicemia, and the predictors were a categorical
variable for early or late post-vaccine period (compared to the prevaccine reference period) and a categorical variable for state. The
incidence rate ratio (IRR) was calculated as the exponent of the
regression coefficient for the post-PCV7 period. To get estimates
for individual years, we used a categorical variable for the number
of years post-PCV7 (rather than a variable for early or late postPCV7 period).
To estimate how these changes in incidence would translate into
cases averted, we multiplied the average number of RSV cases in
our study area for 1997/1998–1999/2000 among children aged ,
2 mo, 3–11 mo, and 12–23 mo by the post-vaccine decline (i.e., 1
2 IRR) observed in each age group for 2004/2005–2008/2009.
This quantity gives an estimate for the number of cases averted
within our study area for each age stratum. This value was then
multiplied by the average population in each age stratum for the
entire United States (1997–1999) and divided by the average
population in our study area to get an estimate of the cases averted
per year across the entire US.
In a sensitivity analysis, we evaluated changes since 1992/1993
in the incidence of hospitalizations coded as bronchiolitis, rather
than changes in the incidence of hospitalizations with an RSVspecific code (these categories are not mutually exclusive). This
analysis was performed because the bronchiolitis codes are less
likely than the RSV codes to be biased by changes in viral testing
or coding and because reliable bronchiolitis data were available
since 1992/1993 (rather than 1997/1998 for RSV).

Regression of RSV on Pneumococcal Pneumonia
To quantify the association of RSV and influenza activity with
pneumococcal disease incidence while controlling for seasonal
variations, we fit a Poisson regression model. This model includes
harmonic variables that cycle every 6 and 12 mo. These variables
capture seasonal fluctuations that are consistent between years and
allow for the comparison of weekly pneumococcal disease rates
and RSV and influenza rates while subtracting out the consistent
seasonal variations. For this analysis, we focused on the period
from 1997/1998 to 2008/2009, which excludes the period prior to
when the ICD-9 codes for RSV changed, and it excludes the
second half of 2009 (which had unreliable influenza coding due to
the 2009 pandemic) and the start of the 13-valent pneumococcal
conjugate vaccine (PCV13) period. The outcome variable was
weekly incidence of pneumococcal pneumonia or pneumococcal
septicemia hospitalizations. The Bayesian information criterion
(BIC) was used to identify the best model. This criterion provides
an estimate of the goodness of fit of the model while including a
penalty for overfitting (including too many variables). The model,
based on Simonsen at al. [27], was
lnðpneumococcal casesÞ~b0 zb1  sinðhÞzb2  cosðhÞ
zb3  sin( )zb4  cos( )zb5  RSV ð2Þ
zb6  FLUztk  periodk zdi  statei
where h = 2*p*week/52.25 and = 2*p*week/26.125. The sine
and cosine terms fit a seasonal baseline using annual and semiannual periods. di estimates the state-specific intercept along with
b0. RSV and FLU are the weekly incidence of RSV and influenza
hospitalizations, respectively, in all ages in each state. tk estimates
the change in incidence between the pre-vaccine period (1997/
1998–1999/2000), early post-vaccine period (2000/2001–2002/
2003), and late post-vaccine period (2003/2004–2008/2009). We
also evaluated simpler and more complex models that included
interaction terms that allowed the seasonal and viral variables to
vary by state. Based on BIC, the model presented above provided
the best fit. Estimates from the alternative models are presented in
Text S1, Table S1, and Figure S4.
PLOS Medicine | www.plosmedicine.org

Results
Study Characteristics
The State Inpatient Databases used for these analyses include
data from 36 states from 1992/1993 to 2008/2009 (Figure S1).
Every hospitalization occurring at a community hospital in the
3
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Table 1. Study characteristics.

Dataset

Data from all
available states

Data from states that
could be stratified by
age 0–2 and 3–11 mo{

Age

0–24 mo

Population
(Person-Years/
1,000,000)

Number of
Admissions
Pneumococcal
Pneumonia

Pneumococcal
Septicemia

RSV

Bronchiolitis

Influenza

11,600

5,804

729,526

—

70,872

70.2

0–11 mo

6,078

3,402

610,871

977,417

48,586

35.3

12–23 mo

5,522

2,402

118,655

—

22,286

34.9

All ages
(incl. adults)

—

—

840,464

—

434,034

2,549.8

0–2 mo

828

436

113,716

—

—

3.5

3–11 mo

1,374

921

113,652

—

—

10.4

Number of admissions for each condition in the included states and cumulative population residing in those states for 1997/1998–2008/2009.
{
Arizona, California, Colorado, Georgia, Iowa, Kansas, Massachusetts, New York, and South Carolina. See Table S1 for the tabulation of cases by state.
doi:10.1371/journal.pmed.1001776.t001

included states is captured in this database, but some states
contributed fewer years of data (Figure S1). For 2008/2009, there
were 6.7 million children aged ,2 y living in the states included in
the database. For the period from 1997/1998 to 2008/2009, there
were 70.2 million person-years of observation for the , 2-y-old
children, including 11,600 hospitalizations coded as pneumococcal
pneumonia and 5,804 hospitalizations coded as pneumococcal
septicemia (Table 1). Additionally, there were 729,526 hospitalizations coded as RSV (since 1997/1998) among , 2-y-old
children (840,464 across all age groups) and 70,872 coded as
influenza among , 2-y-old children (434,034 across all age
groups). There were 977,417 hospitalizations coded as bronchiolitis among , 1-y-old children (3.0 million bronchiolitis
hospitalizations across all age groups).

Florida, where there was a relatively flat, early RSV peak, and
pneumococcal pneumonia cases in children peaked substantially
later. There was also a significant association between the timing
of RSV hospitalizations and the timing of pneumococcal
septicemia hospitalizations (r = 0.59, 95% CI: 0.21, 0.80;
Figure 1), but there was no detectable lag between the RSV and
pneumococcal septicemia epidemic peaks. There was notably
more uncertainty about the timing of the pneumococcal septicemia epidemics because of sparser data (Figure 1).

Association between RSV and Influenza Activity and
Pneumococcal Pneumonia Incidence
We next considered whether seasonal increases in RSV activity
were associated with variations in pneumococcal pneumonia
incidence. Using regression models that controlled for shared
seasonal factors and influenza activity, we evaluated the association between RSV and pneumococcal pneumonia hospitalizations.
Among , 1-y-old infants, 20.3% (95% CI: 17.4%, 25.1%) of
pneumococcal pneumonia cases were associated with RSV activity
(IRR: 1.23, 95% CI: 1.19, 1.30). Further stratification by age
revealed that this association was particularly pronounced in
children aged 0–2 mo, where 35.7% (95% CI: 27.9%, 42.7%) of
pneumococcal pneumonia cases were associated with RSV
(Table 2; Text S1) (IRR: 1.42, 95% CI: 1.30, 1.55). In children
aged 3–11 and 12–23 mo, the estimated association with RSV was
smaller but still significant (AP: 20.0% [95% CI: 14.7%, 24.8%]
and 10.1% [95% CI: 7.6%, 13.9%], respectively; Table 2)
(respectively, IRR: 1.24, 95% CI: 1.17, 1.33; IRR: 1.12, 95%
CI: 1.09, 1.18). The association between RSV and pneumococcal
septicemia hospitalizations was substantially smaller than the
association between RSV and pneumococcal pneumonia hospitalizations, with AP estimates of 0.1%–15.0%, with the strongest
effect in children aged 0–2 mo (Table 2).
Influenza activity was also associated with significant increases
in pneumococcal pneumonia among children aged 3211 and
12223 mo (AP: 2.2% [95% CI: 0.1%, 3.4%] and 3.2% [95% CI:
1.7%, 4.7%], respectively; Table 2). While influenza, compared
with RSV, was associated with a smaller fraction of all
pneumococcal pneumonia cases, the effect was more pronounced
when focusing just on seasons with severe influenza epidemics

Seasonality of RSV, Influenza, and Pneumococcal
Pneumonia
The weekly incidences of RSV and pneumococcal pneumonia
hospitalizations among , 2-y-old children exhibited strong
seasonal variations, with peaks occurring from autumn through
the winter (Figures 1 and 2A). RSV exhibits a distinctive
spatiotemporal pattern, with earlier epidemics in the southern
and eastern United States and later epidemics in the northern and
western states (Figure 1). Influenza epidemics in the United States
also exhibit winter seasonality, with strong year-to-year variations
in intensity (Figure 2B).

Spatiotemporal Association between RSV Activity and
Pneumococcal Hospitalization
We considered whether there was a relationship between the
timing of the peaks of seasonal RSV epidemics and the timing of
the peaks of pneumococcal pneumonia or septicemia hospitalizations in each state. Pneumococcal pneumonia hospitalizations in
, 2-y-old children exhibited a spatiotemporal pattern that was
similar to that of RSV hospitalizations. There was a strong
correlation between the average peak timing across the US of RSV
hospitalizations and pneumococcal pneumonia hospitalizations
(r = 0.70, 95% CI: 0.45, 0.84; Figure 1). On average, the epidemic
timing of pneumococcal pneumonia lagged behind the RSV
epidemics by 1.5 wk (95% CI: 0.8, 2.2; Figure 1). The outlier was
PLOS Medicine | www.plosmedicine.org
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older. However, the magnitude of the AP estimates differed
between models. The results from an additive (identity-linked)
model were higher than those from the multiplicative (log-linked)
model (Figure S2). The association between RSV and pneumococcal pneumonia and the age patterns were confirmed in
sensitivity analyses using models that included seasonally adjusted
viral incidence rather than raw viral incidence (Figure S3).
Variations in how the baseline was modeled had limited influence
on the estimates of the AP (Table S1; Figure S4). Models that
included raw viral incidence fit the data better than models that
included seasonally adjusted viral incidence (Table S1). Lagging
the RSV variable resulted in a poorer fit of the model, while
lagging the influenza variable had no impact on model fit (Table
S2; Figure S5). There is little collinearity between RSV and
influenza (R2 = 0.13, 95% CI: 0.12, 0.14) (Figure 2). Finally,
hospitalizations coded as syndromic bronchiolitis might be less
subject to coding biases than hospitalizations coded as RSV.
Substituting a weekly bronchiolitis variable (Figure S6) for the
weekly RSV variable in the regression resulted in similar estimates
(AP: 24.7% [95% CI: 21.1%, 28.9%] for bronchiolitis compared
with 20.3% [95% CI: 17.4%, 25.1%] for RSV for , 1-y-old
children).

Changes in RSV Activity following the Introduction of
Pneumococcal Conjugate Vaccine
We evaluated whether the incidence of RSV hospitalizations
declined in the years following PCV7 introduction. Comparing the
incidence of RSV hospitalizations in 2004/200522008/2009 with
that in the 3 y prior to PCV7 introduction, there was a significant
decline among , 1-y-old children (218.0%, 95% CI: 222.6%,
213.1%) and a smaller decline among children aged 12223 mo
(29.2%, 95% CI: 215.1%, 22.9%). The decline in RSV was
most apparent among children aged 3211 mo (218.4%, 95% CI:
225.4%, 210.6%). This decline was evident by 2002/2003
(Figures 3 and 4). In comparison to in children aged 3211 mo,
the decline in RSV incidence in children aged 022 mo was more
modest and not significant (26.3%, 95% CI: 214.7%, 2.2%;
Figures 3 and 4). These rates of decline among , 2-y-old children
would translate to 9,970 (95% CI: 3,232, 15,960) fewer RSV
hospitalizations per year if applied to the entire , 2-y-old
population in the US (based on the disease rates and population
size for 199721999).
As a comparison, we also evaluated the timing of the declines in
pneumococcal septicemia and pneumococcal pneumonia cases
after PCV7 introduction. There were sharp and immediate
declines in the incidence of pneumococcal septicemia among the
children aged 022 and 3211 mo starting in 2000/2001
(Figure 3). However, similar to the pattern observed for RSV,
pneumococcal pneumonia incidence declined more among
children aged 3211 mo than among children aged 022 mo
(Figures 3 and 4). The declines in pneumococcal pneumonia and
septicemia incidence were detectable sooner than the decline in
RSV incidence. There was considerable variability in the
magnitude of the estimated change between states for both RSV
and pneumococcal pneumonia (Figures 4 and 5).
Finally, we considered whether the results were sensitive to the
choice of the baseline period. RSV coding changed in 1997,
preventing comparisons with earlier years. However, there is a
strong correlation between weekly hospitalizations coded as
syndromic bronchiolitis and those coded as RSV (R2 = 0.99,
95% CI: 0.98, 0.99; Figure S6). Between the pre-vaccination era,
1997/199821999/2000, and the late post-PCV7 period, 2004/
200522008/2009, bronchiolitis hospitalizations declined by
215.9% (95% CI: 221.8%, 29.5%) among children aged

Figure 1. Relationship in the timing of the average seasonal
peak of RSV, pneumococcal pneumonia, and pneumococcal
septicemia. Association between the average peak timing (in weeks)
of RSV hospitalizations and the average peak timing (in weeks) of (A)
pneumococcal pneumonia hospitalizations and (B) pneumococcal
septicemia hospitalizations in each state among children aged ,2 y,
1992/1993–2008/2009. Smaller values indicate earlier epidemics. The
error bars indicate the 95% confidence intervals. The colors differentiate
the states; labels for selected states are shown.
doi:10.1371/journal.pmed.1001776.g001

(e.g., 2003/2004; Figure 2). For instance, during 2003/2004,
6.6% (95% CI: 3.1%, 10.0%) of pneumococcal pneumonia cases
were associated with influenza among children aged 12223 mo,
compared with 3.2% (95% CI: 1.7%, 4.7%) across all years.
We also explored the sensitivity of the results to different
modeling choices, such as using additive versus multiplicative
models, removing the seasonal component from the viral variables
prior to fitting the model, using different sets of covariates, and
using different lags of the viral variables (Text S1). Regardless of
model choice, the same age pattern emerged, with larger RSVassociated changes in pneumococcal pneumonia among children
aged 022 mo, and smaller changes among those aged 1 y or
PLOS Medicine | www.plosmedicine.org
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Figure 2. Time series of hospitalizations for pneumococcal pneumonia, RSV, and influenza in California. Incidence rate of
pneumococcal pneumonia (red, 3-wk moving average) among children age ,2 y in California compared with the incidence of (A) RSV among
children aged ,2 y (blue) and (B) influenza among all ages (green), 1997/1998–2008/2009. The x-axis shows the year and quarter. Incidence is
defined as cases per 100,000 children.
doi:10.1371/journal.pmed.1001776.g002

RSV activity declined significantly among children aged 3211 mo
after pneumococcal conjugate vaccine (PCV) introduction. These
results, obtained from population-based epidemiological data,
suggest that RSV might increase the risk for pneumococcal
infections and that a subset of hospitalized RSV cases might have a
mixed viral–bacterial etiology. These findings are unique in that
we were able to use data from an unusually large and robust
database to perform detailed age-stratified analyses, to evaluate
spatiotemporal patterns across a large area, and to control for
seasonality using harmonic regression models. Further studies
relying on individual-level data from pneumonia patients will help
to clarify the importance of this association.
Our findings are consistent with some previous studies
demonstrating a link between RSV and pneumococcus. Children

3211 mo. Using an extended pre-vaccine baseline (1992/1993
21999/2000) to estimate post-PCV7 changes in incidence gave a
smaller but still significant decline (212.2%, 95% CI: 218.3%,
25.6%).

Discussion
Using hospitalization records from a large database covering the
majority of states in the United States, we have found evidence
supporting an association between pneumococcus and RSV
infections. Seasonal epidemics of hospitalizations due to RSV
and pneumococcal pneumonia shared a distinctive spatiotemporal
pattern, variations in RSV activity were associated with substantial
subsequent increases in pneumococcal pneumonia incidence, and

Table 2. Percent of pneumococcal pneumonia and pneumococcal septicemia cases attributable to RSV and influenza in children
aged ,2 y, 1997/1998–2008/2009.

Disease
Pneumococcal pneumonia

Pneumococcal septicemia

Age

RSV AP (95% CI)

Influenza AP (95% CI)

0–11 mo

20.3 (17.4, 25.1)

0.6 (20.9, 1.4)

0–2 mo

35.7 (27.9. 42.7)

2.1 (24.5, 7.9)

3–11 mo

20.0 (14.7, 24.8)

2.2 (0.1, 3.4)

12–23 mo

10.1 (7.6, 13.9)

3.2 (1.7, 4.7)

0–11 mo

7.2 (5.3, 9.0)

20.6 (21.4, 0.3)

0–2 mo

15.0 (13.1, 17.1)

0.7 (21.1, 2.2)

3–11 mo

0.1 (24.9, 5.0)

22.7 (23.7, 21.7)

12–23 mo

3.8 (2.5, 5.2)

1.9 (1.1, 2.6)

The estimates of the AP are calculated using the results of the regression model by dividing the number of pneumococcal disease cases predicted if RSV were not
present by the number of pneumococcal disease cases predicted based on the observed incidence of RSV.
doi:10.1371/journal.pmed.1001776.t002
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Figure 3. Change in hospitalization rates in each year
compared with the average of 1997/1998–1999/2000 among
children aged 0–2 and 3–11 mo for RSV, pneumococcal
pneumonia, and pneumococcal septicemia. The y-axis is the IRR
and 95% confidence intervals, with values below one representing
declines compared with the baseline period.
doi:10.1371/journal.pmed.1001776.g003

hospitalized with RSV had a higher risk for developing invasive
pneumococcal infections [10], and a randomized controlled trial
demonstrated that children aged .4 mo who received PCV had
lower rates of RSV hospitalizations than those who did not [13].
The magnitude of the observed change in RSV hospitalization
rates among children aged 3211 mo from our study is comparable to that found in the randomized controlled trial of PCV [13].
Likewise, a study from Alaska found that RSV pneumonia rates
were declining in recent years, with the authors suggesting that the
decline could be due to RSV prophylaxis or possibly to PCV7
[29]. A previous study found a link between bronchiolitis
admissions (a proxy for RSV disease) and invasive pneumococcal
pneumonia cases in children [11]. Other studies also identified a
correlation between the seasonal timing of RSV and pneumococcal disease epidemics [4,18,19], although some of these previous
analyses did not control for the shared winter seasonality of the
epidemics, which is critical for proper interpretation. A recent
study in England and Wales [17] found no association between
RSV and invasive pneumococcal disease among children aged ,
5 y. In our study, the association was weaker for pneumococcal
septicemia than for pneumococcal pneumonia and was weaker in
older children. Therefore, we suggest that future analyses in this
area should account for the clinical syndrome of the invasive
pneumococcal disease cases and should focus on younger children.
Mechanistically, these results support the notion that a primary
RSV infection increases the risk for a secondary pneumococcal
pneumonia infection. Recent experimental work demonstrates
that RSV can directly bind to pneumococcal surface proteins and
influence the virulence of the bacteria [15]. With such a direct
mechanism, we would expect that RSV activity would increase
first, and pneumococcal disease rates would increase either at the
same time or within a short time period. The ,1.5-wk lag between
PLOS Medicine | www.plosmedicine.org

Figure 4. Variations between states and age groups in the
change in rates of hospitalization for RSV or pneumococcal
pneumonia after introduction of PCV7. Decline in the rate of (A)
RSV hospitalizations and (B) pneumococcal pneumonia hospitalizations
in each state for 2004/200522008/2009 compared with the average of
1997/199821999/2000 for children aged 0211, 022, 3211, and 122
23 mo. The IRRs are shown, with values below one indicating a decline
compared with the baseline period. The size of the bubbles is
proportional to the inverse variance (i.e., more confidence in larger
bubbles). Fewer states were available for the analysis of children aged
022 and 3211 mo. The lines demonstrate the difference in IRRs
between children aged 022 and 3211 mo. The colors differentiate the
states.
doi:10.1371/journal.pmed.1001776.g004

the epidemic peaks of RSV and pneumococcal pneumonia is
consistent with such a mechanism.
The observed decline in RSV hospitalizations could be
consistent with the notion that some fraction of the cases
diagnosed with RSV have a mixed bacterial–viral etiology. For
example, in some cases, a child could have a mild or asymptomatic
RSV infection, pneumococcus makes it severe and leads to
hospitalization, but only RSV infection is diagnosed. In such a
scenario, elimination of virulent pneumococci with PCVs would
reduce the rate of diagnosed RSV hospitalizations.
7
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Figure 5. Variations between states, age groups, and years in
the change in rates of hospitalization for RSV or pneumococcal
pneumonia after introduction of PCV7. Decline in the rate of (A)
RSV hospitalizations and (B) pneumococcal pneumonia hospitalizations
in each state and each year (July2June) among children aged 0211 mo
compared to the average of 1997/199821999/2000 in the same state.
The shaded areas indicate the 95% confidence intervals for the IRRs. The
red dotted line indicates a rate ratio of one (no change). The colors
differentiate the states.
doi:10.1371/journal.pmed.1001776.g005

The finding of a relationship between RSV and pneumococcal
disease seemingly contradicts some previous studies that suggested
that secondary bacterial infections do not commonly follow RSV
[16,30]. However, this issue can be resolved by considering that
there are actually two separate but related questions. The first
question is whether RSV and pneumococcus interact, and
whether this synergism leads to higher rates of hospitalization
attributed to one or both pathogens. This issue is important for
determining what interventions might prevent hospitalizations
caused by RSV or respiratory bacteria. Our results support the
notion that these pathogens do interact and that some ‘‘RSV
hospitalizations’’ might have a mixed viral–bacterial etiology.
The second question is whether children hospitalized with RSV
are at increased risk for developing a secondary bacterial infection
that could be prevented or treated with antibiotics. Studies of this
issue have reported seemingly conflicting findings. Some have
demonstrated that RSV cases do not have subsequent bacteremia
[16], but others have found evidence of a relationship between RSV
and subsequent bacterial infections [10,31]. This apparent conflict
could be a matter of these studies considering the absolute versus
relative risk. There are many RSV hospitalizations in children, but
comparatively few cases of bacteremia (and bacteremia is an
insensitive method for detecting bacterial infections). It is possible
that a large percentage of bacterial pneumonia cases could be
attributable to RSV (as our data suggest for young children), but a
smaller percentage of RSV cases might have bacterial co-infections.
Additionally, the inflammatory damage caused by the secondary
bacterial infection could occur prior to a child visiting a clinician.
Such a phenomenon could explain why clinical trials of antibiotics
to treat bronchiolitis have shown limited effects [32]. Our data
suggest that bacterial co-infection could be considered in children
hospitalized with pneumonia (rather than bronchiolitis), even those
who test positive for RSV infection, and antibiotic treatment might
be appropriate in some instances.
The age pattern observed here—with a moderate post-PCV7
decline in RSV and pneumococcal pneumonia in children aged
3211 mo but no change in RSV among children aged ,3 mo—is
somewhat surprising but is consistent with one prior study that
showed that PCV7 had limited impact in children aged ,3 mo
because of higher levels of serotype replacement [25]. Likewise,
our finding of a significant decline in pneumococcal septicemia is
consistent with studies that detected a decline in invasive
pneumococcal disease among neonates [33,34]. There are several
potential explanations for these patterns. First, it is possible that
pneumococcal septicemia and pneumococcal pneumonia have
different risk factors: the children who get sick with pneumococcal
pneumonia might be susceptible to whatever pneumococcus they
are exposed to, regardless of serotype, so increases in carriage of
non-vaccine serotypes might have a large impact. In contrast, for
the children who get sick with pneumococcal septicemia, the
specific serotype they are exposed to might be more important, so
exposure to the less invasive non-vaccine serotypes might not
increase the risk for disease. Additionally, administration of
nine-valent PCV in children at 6 and 14 wk of age has been
PLOS Medicine | www.plosmedicine.org
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temporally associated with an increased risk of RSV hospitalization [35].
The data used in our analyses end in 2009, just prior to the
introduction of PCV13 in the United States. This next-generation
pneumococcal vaccine has further decreased the incidence of
pneumococcal disease [36]. However, we expect that the
interaction between pneumococcus and RSV will still be
important. The vaccine has likely changed the distribution of
serotypes causing disease in children. However, pneumococcus is
still commonly carried among healthy children [37], and recent
evidence suggests that RSV directly binds to a conserved
pneumococcal surface protein present in all serotypes [15].
Therefore, we expect that RSV will still be associated with
increases in the incidence of pneumococcal disease caused by nonvaccine serotypes, even if the overall incidence of pneumococcal
disease has declined.
It will be necessary to repeat these types of analyses in resourcepoor countries to understand the relative importance of coinfections in these settings. The burdens of both RSV and
pneumococcal disease are particularly high in resource-poor
settings [9,38]. Bacterial–viral interactions could be particularly
important in understanding and quantifying the impacts of
vaccines against pneumococcus, which are now being deployed
in many resource-poor settings around the world. For instance,
studies that focus on pathogen-specific outcomes (e.g., pneumococcal septicemia) will likely underestimate the full impacts of the
vaccine. Likewise, future interventions targeting RSV (e.g.,
maternal immunization) could have secondary effects against
pneumococcus or other bacterial pathogens. Understanding the
strength of these interactions could help to predict the full impact
of an RSV vaccine program.
The strength of the association between RSV and pneumococcus could differ in resource-poor settings. It is possible that host
factors, such as immunodeficiencies or nutritional problems,
contribute more to the burden of pneumococcal disease in
developing countries, making the relative contribution of respiratory viruses less or more important (e.g., a smaller or larger AP).
Further time series studies in resource-poor settings with highquality data, such as in South Africa [13,39,40], could help to
clarify this interaction in different risk groups.
Other studies on this topic have used weather variables to control
for shared seasonal timing [12,17,41] rather than harmonic
variables, which was the approach used here. Since there is not a
clear causal link between weather and RSV or pneumococcal
disease (and if there is a link, it could be nonlinear), we used
harmonic variables to avoid introducing an additional source of
uncertainty. However, there could be other confounders not
captured by the harmonic terms that could influence the results.
For instance, dynamic processes (such as waning immunity) could
be synchronized by a common environmental risk factor and could
lead to similar epidemic timing for RSV and pneumococcus.
Our study and interpretations have several caveats. These
analyses define disease rates on the basis of hospitalization
discharge codes rather than direct microbiological evidence. As
a result, it is possible that cases coded as pneumococcal
pneumonia/lobar pneumonia might not have a pneumococcal
etiology. If some of the pneumococcal pneumonia cases are, in
fact, RSV cases without a bacterial co-infection, then this would
lead to higher estimates of AP. Few RSV cases result in lobar
pneumonia [42] (which shares an ICD-9 code with pneumococcal pneumonia), decreasing the chances of such misclassification. While ICD-9 codes for pneumococcal pneumonia and
septicemia are sensitive and specific in some settings [43], they
have not been specifically validated in children or following
PLOS Medicine | www.plosmedicine.org

vaccine introduction. Therefore, potential misclassification of
cases presents an important source of uncertainty that we are
not able to capture with our models. The estimates of postvaccine changes in disease incidence are based on populationlevel data and could be subject to confounding by changes in
demographics, medical practice, viral testing, and discharge
coding. Additionally, changes in the use of palivizumab in highrisk children could also have reduced RSV hospitalization rates
over time. Therefore, our results will need to be replicated with
different study designs (such as a prospective cohort study) to
determine whether there is a causal link between PCV
introduction and RSV incidence.
The proxies that we use for viral activity—hospitalizations coded
as RSV or influenza—are subject to limitations. The number of
hospitalizations coded for influenza or RSV will almost certainly
underestimate the true number of cases [41]. However, for the
purposes of regression modeling, the timing and amplitude of the
epidemics—rather than their absolute magnitude—would influence
the results. We would not expect biases in coding to influence the
relative timing or amplitude of the epidemics. Because of known
biases in influenza testing and coding by age group, we used influenza
cases aggregated across all age groups. We would expect that
epidemic timing would not vary substantially between age groups in a
given location [44], so this is unlikely to influence our results.
Finally, all of these analyses rely on data aggregated into broad
categories. Such ecological analyses are subject to potential biases
and should be interpreted with caution. While the results support
the hypothesis that RSV and pneumococcus interact, further
individual-level studies of pediatric pneumonia cases would help to
support these findings. Given our results here, we would expect to
find the greatest evidence of an interaction between RSV and
pneumococcus among children aged ,1 y, and particularly
among neonatal pneumonia cases. One approach would be to
look for evidence of a recent RSV infection among neonatal
pneumonia cases with confirmed evidence of pneumococcal
disease (or other bacterial pneumonias) and compare these cases
to an appropriate control group.
In conclusion, our analyses suggest that there is a relationship
between RSV and pneumococcal pneumonia hospitalizations,
supporting previous observations in a randomized clinical trial
[13]. RSV is associated with increases in the incidence of
pneumococcal pneumonia, particularly in young infants, and a
percentage of RSV hospitalizations might be attributable to
pneumococcus, based on post-PCV7 declines. These findings
could help in the design of more effective interventions to treat
respiratory infections in young children.

Supporting Information
Figure S1 Years and states included in each analysis. A
black mark indicates that the state and year was included in the
analysis. The red vertical line indicates the time of PCV7
introduction in the United States. The states are sorted based on
the first year available for each analysis. For the pre/post-PCV7
incidence graph, the states highlighted in red had data available
for ,1-y-old children that could be further stratified by 0–2 and
3–11 mo of age.
(PDF)
Figure S2 Estimates of the RSV attributable percent in
each age group calculated with a multiplicative Poisson
model or an additive linear model. The diagonal line
denotes x = y.
(TIF)
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Figure S3 Estimates of the RSV attributable percent in
each age group from a multiplicative model where the
RSV variable is raw RSV counts compared with
incidence rate ratio estimates from a model that used
seasonally adjusted RSV counts. Raw RSV counts (y-axis);
seasonally adjusted RSV counts (x-axis).
(TIF)

BIC scores show the BIC in each age group. Models 1–18 include
unadjusted RSV and influenza incidence, while models 19–36
include the seasonally adjusted incidence. The models with the
lowest BIC score for each age group are highlighted.
(DOCX)
Table S2 Effect of lagging the RSV and influenza

variables on the fit of the models. Lower BIC scores indicate
better fit. A lag of zero indicates that the viral time series and the
pneumococcal pneumonia time series are synchronous. A negative
value indicates that the pneumococcal pneumonia time series
follows the viral time series by n weeks. Models were fit to
pneumococcal pneumonia data from children aged 0–11 mo.
(DOCX)

Figure S4 Estimates of the RSV attributable percent

from different candidate models. The size of the circle is
proportional to the BIC weights, and the number indicates which
model was used to generate the estimate (see Table S1 for model
numbers).
(TIF)
Figure S5 Estimates of the RSV and influenza attributable percent in each age group from a multiplicative
model where the influenza and RSV variables were
lagged as in Table S2. The similarity of the estimates indicates
that all of the well-fitting models produced similar estimates of the
AP. The numbers on the graph indicate the model used (from
Table S2) to calculate the AP.
(TIF)

Text S1 Supplementary analyses include sensitivity
analyses related to the choice of the model structure
and lags of the viral incidence variables.
(DOCX)
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Editors’ Summary
pneumonia cases were associated with RSV activity; among
children 1–2 years old, 10.1% of pneumococcal pneumonia
cases were associated with RSV activity. Finally, the
researchers report that following the introduction of routine
vaccination in the US against S. pneumoniae with PCV7 in
2000, there was a significant decline in hospitalizations for
RSV among children under one year old.

Background Respiratory infections—bacterial and viral
infections of the lungs and the airways (the tubes that take
oxygen-rich air to the lungs)—are major causes of illness and
death in children worldwide. Pneumonia (infection of the
lungs) alone is responsible for about 15% of all child deaths.
The leading cause of bacterial pneumonia in children is
Streptococcus pneumoniae, which is transmitted through
contact with infected respiratory secretions. S. pneumoniae
usually causes noninvasive diseases such as bronchitis, but
sometimes the bacteria invade the lungs, the bloodstream,
or the covering of the brain, where they cause pneumonia,
septicemia, or meningitis, respectively. These potentially fatal
invasive pneumococcal diseases can be treated with antibiotics but can also be prevented by vaccination with
pneumococcal conjugate vaccines such as PCV7. The leading
cause of viral pneumonia is respiratory syncytial virus (RSV),
which is also readily transmitted through contact with
infected respiratory secretions. Almost all children have an
RSV infection before their second birthday—RSV usually
causes a mild cold-like illness. However, some children
infected with RSV develop pneumonia and have to be
admitted to hospital for supportive care such as the
provision of supplemental oxygen; there is no specific
treatment for RSV infection.

What Do These Findings Mean? These findings provide
evidence for an interaction between RSV and pneumococcal
pneumonia and indicate that RSV is associated with
increases in the incidence of pneumococcal pneumonia,
particularly in young infants. Notably, the finding that RSV
hospitalizations declined after the introduction of routine
pneumococcal vaccination suggests that some RSV hospitalizations may have a joint viral–bacterial etiology (cause),
although it is possible that PCV7 vaccination reduced the
diagnosis of RSV because fewer children were hospitalized
with pneumococcal disease and subsequently tested for RSV.
Because this is an ecological study (an observational
investigation that looks at risk factors and outcomes in
temporally and geographically defined populations), these
findings do not provide evidence for a causal link between
hospitalizations for RSV and pneumococcal pneumonia. The
similar spatiotemporal patterns for the two infections might
reflect another unknown factor shared by the children who
were hospitalized for RSV or pneumococcal pneumonia.
Moreover, because pooled hospitalization discharge data
were used in this study, these results need to be confirmed
through analysis of individual-level, laboratory-confirmed
data. Importantly, however, these findings support the
initiation of studies to determine whether treatment for
bacterial infections should be considered for children with
pneumonia even if they have tested positive for RSV.

Why Was This Study Done? Co-infections with bacteria
and viruses can sometimes have a synergistic effect and lead
to more severe disease than an infection with either type of
pathogen (disease-causing organism) alone. For example,
influenza infections increase the risk of invasive pneumococcal disease. But does pneumococcal disease also interact
with RSV infection? It is important to understand the
interaction between pneumococcal disease and RSV to
improve the treatment of respiratory infections in young
children, but the importance of bacterial infections following
RSV infection is currently unclear. Here, the researchers
undertake a time series analysis of US hospitalization data to
investigate the association between RSV activity and
pneumococcal disease in infants. Time series analysis uses
statistical methods to analyze data collected at successive,
evenly spaced time points.

Additional Information Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001776.
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What Did the Researchers Do and Find? For their
analysis, the researchers used data collected between 1992/
1993 and 2008/2009 by the State Inpatient Databases on
more than 700,000 hospitalizations for RSV and more than
16,000 hospitalizations for pneumococcal pneumonia or
septicemia among children under two years old in 36 US
states. Using a statistical technique called harmonic regression to measure seasonal variations in disease incidence (the
rate of occurrence of new cases of a disease), the researchers
show that RSV and pneumococcal pneumonia shared a
distinctive spatiotemporal pattern over the study period.
Next, using Poisson regression models (another type of
statistical analysis), they show that RSV was associated with
significant increases (increases unlikely to have happened by
chance) in the incidence of pneumococcal disease. Among
children under one year old, 20.3% of pneumococcal
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The US National Heart, Lung, and Blood Institute
provides information about the respiratory system and
about pneumonia
The US Centers for Disease Control and Prevention
provides information on all aspects of pneumococcal
disease and pneumococcal vaccination, including personal stories and information about RSV infection
The UK National Health Service Choices website
provides information about pneumonia (including a
personal story) and about pneumococcal diseases
KidsHealth, a website provided by the US-based nonprofit Nemours Foundation, includes information on
pneumonia and on RSV (in English and Spanish)
MedlinePlus provides links to other resources about
pneumonia, RSV infections, and pneumococcal
infections (in English and Spanish)
HCUPnet provides aggregated hospitalization data from
the State Inpatient Databases used in this study
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